Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.86 |
| ▸ | INSR | P06213 | 16/20 | 0.86 |
| ▸ | IGF1R | P08069 | 16/20 | 0.86 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | ROS1 | P08922 | 2/20 | 0.81 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.81 |
| ▸ | EGFR | P00533 | 2/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.77 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | STK10 | O94804 | 1/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.77 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.77 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | CD74 | P04233 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | FES | P07332 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090726 | 0.94 | ALK (0.82) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916520 | 0.93 | INSR (0.98) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916513 | 0.93 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL28680439 | 0.92 | ALK (0.84) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916443 | 0.92 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916537 | 0.92 | INSR (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL24818137 | 0.92 | ALK (0.83) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916432 | 0.92 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916456 | 0.92 | ALK (0.85) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL21135587 | 0.92 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20210355146-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | ARIAD PHARMACEUTICALS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-10934317-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine | ARIAD PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10385078-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | ARIAD PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180037597-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20180037597-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024620-A1 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024620-A1 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355146-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | ERBB2, ERBB4, CDK2 | ALK 20/4885INSR 1217/4885IGF1R 500/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885IGF1R 526/4885 |
| US-20140024620-A1 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, ERBB2, MKI67 | ALK 28/4885INSR 816/4885IGF1R 37/4885 |
| US-10385078-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | ERBB2, ABL1, CDK2 | ALK 25/4885INSR 1242/4885IGF1R 509/4885 |
| US-20180037597-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE | ERBB2, ABL1, ERBB4 | ALK 12/4885INSR 951/4885IGF1R 389/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | ALK 370/4885INSR 751/4885IGF1R 477/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALK 5/4885INSR 1929/4885IGF1R 306/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885IGF1R 526/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-10934317-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine | ERBB2, ABL1, CDK2 | ALK 25/4885INSR 1242/4885IGF1R 509/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885IGF1R 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.